To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Canbex Therapeutics Secures TSB Biocatalyst Grant
Canbex Therapeutics Ltd announced that it has secured a grant of £1.25M to further support the development of VSN16R. Alongside our recent financing round the grant secures the early development of this novel treatment for spasticity in multiple sclerosis.
“The goal of the Canbex programme is to set a new standard in the treatment of spasticity through improved tolerability,” said Jesse Schulman, CEO of Canbex. “Spasticity is among the most serious and debilitating symptoms of MS. VSN16R, our lead investigational candidate, has the potential to make a difference to people with MS.”
- multiple sclerosis
- 1Scientists get first glimpse of a chemical bond being born
- 2Penta-graphene, a new structural variant of carbon, discovered
- 3Novozymes, Cargill continue bio-acrylic acid partnership as BASF exits
- 4Bio-succinic Acid Wins Biofuels Digest Chemical Of The Year Award
- 5WACKER Closes 2014 Ahead of Expectations
- 6Better batteries inspired by lowly snail shells
- 7Scientists set quantum speed limit
- 8Breakthrough may lead to industrial production of graphene devices
- 9Evidence mounts for quantum criticality theory
- 10BASF starts Open Innovation contest on energy storage
- EPSRC unveils world-leading SuperSTEM microscope that sees single atoms
- Chemists control structure to unlock magnetization and polarization simultaneously
- Is glass a true solid?
- SP Acquires Stability Environments
- Global ammonia capacity will increase from 204.2 million tons per year (mmty) in 2013 to 249.4 mmty by 2018